latozinemab
latozinemab: sourced relationships with 1 company · 1 clinical trial tracked.
latozinemab evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect latozinemab to ALEC; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could latozinemab → ALEC affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Amyotrophic Lateral Sclerosis; Frontotemporal DementiaNeurodegenerative Diseases
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Alector, Inc. (ALEC) Amyotrophic Lateral Sclerosis; Frontotemporal Dementia | Phase 3 |
Clinical Trial Registry Records (1)
A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease
Primary endpoint: Number of participants receiving latozinemab
Interventionalopen17 targetStarted 2023-12Completion 2026-0118 sites · Belgium, Canada, France, Germany…Alector Inc.
Frequently asked questions
Which companies have sourced relationships with latozinemab?
latozinemab has dated SEC/FDA relationship records for Alector, Inc..
How many clinical trials involve latozinemab?
BioSniper tracks 1 clinical trial involving latozinemab.